September 14th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.
September 11th 2023
September 10th 2023
September 10th 2023
September 6th 2023
No Benefit to Neoadjuvant Durvalumab/Chemo Followed by Adjuvant Durvalumab in EGFR+ NSCLC
September 11th 2023Data from a subgroup of patients with EGFR-mutated non–small cell lung cancer showed that an experimental treatment strategy using durvalumab and chemotherapy is not beneficial for patients.
Read More
Reviewing OPAL Results in EGFR+ NSCLC Before Phase 3 FLAURA2 Presentation
August 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.
Read More
REZILIENT3: Evaluating Zipalertinib/Chemo in EGFR Exon20ins+ NSCLC
August 7th 2023Determining the safety and efficacy of zipalertinib combined with chemotherapy for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer are the key goals of the newly-launched phase 3 REZILIENT3 study.
Read More
Chemotherapy Regimens Remain Key to Survival in Post EGFR-TKI NSCLC Harboring EGFR Mutations
July 10th 2023The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor. But chemotherapy regimens remain standard.
Read More
Treatment for EGFR-Mutant NSCLC Varies by Driver
June 30th 2023In an interview with Targeted Oncology, Nicholas Girard, MD, PhD reviews 3 key abstracts presented at the ELCC 2023, in which different targeted therapies were administered to patients with EGFR-mutant non–small cell lung cancer in clinical trial and real-world settings.
Read More
MET Overexpression as a Predictive Biomarker in Post-Osimertinib NSCLC
June 26th 2023In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Read More
Adding Pembrolizumab to Chemo Does Not Significantly Improve Survival in EGFR+ NSCLC
June 6th 2023Data presented at the ASCO 2023 Annual Meeting showed that the addition of pembrolizumab to pemetrexed and platinum-based chemotherapy did not statistically improve survival in patients with TKI-resistant EGFR-mutated non–small cell lung cancer.
Read More
Areas of Concern in Using Amivantamab and Mobocertinib in EGFR Exon 20+ NSCLC
May 11th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed with participants how they would use the FDA-approved therapies amivantamab and mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion alteration. This is the second of 2 articles based on this event.
Read More
Sintilimab Plus Bevacizumab and Chemo Prolongs PFS in TKI-Refractory EGFR+ NSCLC
May 8th 2023New results from ORIENT-31 show a sustained progression-free survival benefit and overall survival improvement trend in patients with EGFR-mutant non–small cell lung cancer who failed a tyrosine kinase inhibitor previously.
Read More
FDA Approves FoundationOne® Liquid CDx as Companion Diagnostic for Mobocertinib in EGFRm NSCLC
May 4th 2023The FoundationOne® Liquid CDx has been granted approval by the FDA as a companion diagnostic for mobocertinib for patients with locally advanced or metastatic non–small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
Amivantamab Compared With Real-World EGFR Exon 20 NSCLC Population
April 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.
Read More
Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors
April 7th 2023A first-in-human study is assessing the safety, efficacy, and pharmacokinetics of DK210 as a monotherapy and in combination with immunotherapy, radiotherapy, or chemotherapy for patients with EGFR-expressing solid tumors.
Read More
Burns Compares Therapies Approved for NSCLC With an EGFR Exon 20 Insertion Mutation
March 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the trials supporting the use of mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Read More
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.
Read More
Telisotuzumab Vedotin With Erlotinib Appears Promising in EGFR-Mutant, c-Met NSCLC
February 20th 2023The combination of telisotuzumab vedotin and erlotinib did not lead to any unexpected safety signals and showed encouraging antitumor activity in patients with EGFR-mutated, c-Met protein expressing non–small cell lung cancer.
Read More
China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS Metastases
January 30th 2023The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.
Read More
FDA Accepts IND for HT-001 for EGFRi-Associated Rash and Skin Disorders
January 17th 2023Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.
Read More
Piotrowska Looks at Amivantamab and Mobocertinib for Patients With Rare Driver Mutations in NSCLC
January 16th 2023During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Read More